Figures & data
Table 1. Polymer: drug ratios of the prepared samples.
Figure 2. FE-SEM images of Prop. HCl-eudragit® RS100 electrosprayed formulations with the polymer:drug ratios and solution concentrations of (a) 5:1–10% (w/v), (b) 5:1 – 15% (w/v), (c) 5:1 – 20% (w/v), (d) 10:1 – 10% (w/v), (e) 10:1 – 15% (w/v) and (f) 10:1 – 20% (w/v).
![Figure 2. FE-SEM images of Prop. HCl-eudragit® RS100 electrosprayed formulations with the polymer:drug ratios and solution concentrations of (a) 5:1–10% (w/v), (b) 5:1 – 15% (w/v), (c) 5:1 – 20% (w/v), (d) 10:1 – 10% (w/v), (e) 10:1 – 15% (w/v) and (f) 10:1 – 20% (w/v).](/cms/asset/f231667a-6b8b-442a-9687-fd755d16b6a2/ianb_a_1337027_f0002_c.jpg)
Figure 3. DSC thermograms of the pure Prop. HCl; eudragit® RS100; PM (physical mixture) and NP (electrosprayed nanoformulations) with a polymer:drug ratio of 5:1 and the total solution concentrations of 10% and 20% (w/v).
![Figure 3. DSC thermograms of the pure Prop. HCl; eudragit® RS100; PM (physical mixture) and NP (electrosprayed nanoformulations) with a polymer:drug ratio of 5:1 and the total solution concentrations of 10% and 20% (w/v).](/cms/asset/0cfeb456-104d-41c8-9aeb-5dfa82a8bd62/ianb_a_1337027_f0003_b.jpg)
Figure 4. PXRD patterns of Prop. (Pure drug), Eudragit® RS100, PM (physical mixture) and NP (electrosprayed nanoformulations) with a polymer:drug ratio of 5:1 and the total solution concentrations of 10% and 20% (w/v).
![Figure 4. PXRD patterns of Prop. (Pure drug), Eudragit® RS100, PM (physical mixture) and NP (electrosprayed nanoformulations) with a polymer:drug ratio of 5:1 and the total solution concentrations of 10% and 20% (w/v).](/cms/asset/29fee361-2456-473d-b2b1-34a285968f3f/ianb_a_1337027_f0004_b.jpg)